Mycand loss of p53 cooperate to drive formation of choroid plexus carcinoma

Jun Wang, Diana M. Merino, Nicholas Light, Brian L. Murphy, Yong Dong Wang, Xiaohui Guo, Andrew P. Hodges, Lianne Q. Chau, Kun Wei Liu, Girish Dhall, Shahab Asgharzadeh, Erin N. Kiehna, Ryan J. Shirey, Kim D. Janda, Michael D. Taylor, David Malkin, David W. Ellison, Scott R. VandenBerg, Charles G. Eberhart, Rosalie Sears & 3 others Martine F. Rousse, Richard J. Gilbertson, Robert J. Wechsler-Reya

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Choroid plexus carcinoma (CPC) is a rare brain tumor that occurs most commonly in very young children and has a dismal prognosis despite intensive therapy. Improved outcomes for patients with CPC depend on a deeper understanding of the mechanisms underlying the disease. Here we developed transgenic models of CPCs by activating the Myc oncogene and deleting the Trp53 tumor suppressor gene in murine neural stem cells or progenitors. Murine CPC resembled their human counterparts at a histologic level, and like the hypodiploid subset of human CPC, exhibited multiple wholechromosome losses, particularly of chromosomes 8, 12, and 19. Analysis of murine and human CPC gene expression profiles and copy number changes revealed altered expression of genes involved in cell cycle, DNA damage response, and cilium function. High-throughput drug screening identified small molecule inhibitors that decreased the viability of CPC. These models will be valuable tools for understanding the biology of choroid plexus tumors and for testing novel approaches to therapy. Significance: This study describes new mouse models of choroid plexus carcinoma and uses them to investigate the biology and therapeutic responsiveness of this highly malignant pediatric brain tumor.

Original languageEnglish (US)
Pages (from-to)2208-2219
Number of pages12
JournalCancer Research
Volume79
Issue number9
DOIs
StatePublished - Jan 1 2019

Fingerprint

Brain Neoplasms
Choroid Plexus Neoplasms
Chromosomes, Human, Pair 19
Chromosomes, Human, Pair 12
Chromosomes, Human, Pair 8
Preclinical Drug Evaluations
myc Genes
Neural Stem Cells
Cilia
Choroid Plexus Carcinoma
Tumor Suppressor Genes
Transcriptome
DNA Damage
Cell Cycle
Therapeutics
Pediatrics
Gene Expression

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wang, J., Merino, D. M., Light, N., Murphy, B. L., Wang, Y. D., Guo, X., ... Wechsler-Reya, R. J. (2019). Mycand loss of p53 cooperate to drive formation of choroid plexus carcinoma. Cancer Research, 79(9), 2208-2219. https://doi.org/10.1158/0008-5472.CAN-18-2565

Mycand loss of p53 cooperate to drive formation of choroid plexus carcinoma. / Wang, Jun; Merino, Diana M.; Light, Nicholas; Murphy, Brian L.; Wang, Yong Dong; Guo, Xiaohui; Hodges, Andrew P.; Chau, Lianne Q.; Liu, Kun Wei; Dhall, Girish; Asgharzadeh, Shahab; Kiehna, Erin N.; Shirey, Ryan J.; Janda, Kim D.; Taylor, Michael D.; Malkin, David; Ellison, David W.; VandenBerg, Scott R.; Eberhart, Charles G.; Sears, Rosalie; Rousse, Martine F.; Gilbertson, Richard J.; Wechsler-Reya, Robert J.

In: Cancer Research, Vol. 79, No. 9, 01.01.2019, p. 2208-2219.

Research output: Contribution to journalArticle

Wang, J, Merino, DM, Light, N, Murphy, BL, Wang, YD, Guo, X, Hodges, AP, Chau, LQ, Liu, KW, Dhall, G, Asgharzadeh, S, Kiehna, EN, Shirey, RJ, Janda, KD, Taylor, MD, Malkin, D, Ellison, DW, VandenBerg, SR, Eberhart, CG, Sears, R, Rousse, MF, Gilbertson, RJ & Wechsler-Reya, RJ 2019, 'Mycand loss of p53 cooperate to drive formation of choroid plexus carcinoma', Cancer Research, vol. 79, no. 9, pp. 2208-2219. https://doi.org/10.1158/0008-5472.CAN-18-2565
Wang J, Merino DM, Light N, Murphy BL, Wang YD, Guo X et al. Mycand loss of p53 cooperate to drive formation of choroid plexus carcinoma. Cancer Research. 2019 Jan 1;79(9):2208-2219. https://doi.org/10.1158/0008-5472.CAN-18-2565
Wang, Jun ; Merino, Diana M. ; Light, Nicholas ; Murphy, Brian L. ; Wang, Yong Dong ; Guo, Xiaohui ; Hodges, Andrew P. ; Chau, Lianne Q. ; Liu, Kun Wei ; Dhall, Girish ; Asgharzadeh, Shahab ; Kiehna, Erin N. ; Shirey, Ryan J. ; Janda, Kim D. ; Taylor, Michael D. ; Malkin, David ; Ellison, David W. ; VandenBerg, Scott R. ; Eberhart, Charles G. ; Sears, Rosalie ; Rousse, Martine F. ; Gilbertson, Richard J. ; Wechsler-Reya, Robert J. / Mycand loss of p53 cooperate to drive formation of choroid plexus carcinoma. In: Cancer Research. 2019 ; Vol. 79, No. 9. pp. 2208-2219.
@article{00f753760cb34bc4a73d48d5321b3879,
title = "Mycand loss of p53 cooperate to drive formation of choroid plexus carcinoma",
abstract = "Choroid plexus carcinoma (CPC) is a rare brain tumor that occurs most commonly in very young children and has a dismal prognosis despite intensive therapy. Improved outcomes for patients with CPC depend on a deeper understanding of the mechanisms underlying the disease. Here we developed transgenic models of CPCs by activating the Myc oncogene and deleting the Trp53 tumor suppressor gene in murine neural stem cells or progenitors. Murine CPC resembled their human counterparts at a histologic level, and like the hypodiploid subset of human CPC, exhibited multiple wholechromosome losses, particularly of chromosomes 8, 12, and 19. Analysis of murine and human CPC gene expression profiles and copy number changes revealed altered expression of genes involved in cell cycle, DNA damage response, and cilium function. High-throughput drug screening identified small molecule inhibitors that decreased the viability of CPC. These models will be valuable tools for understanding the biology of choroid plexus tumors and for testing novel approaches to therapy. Significance: This study describes new mouse models of choroid plexus carcinoma and uses them to investigate the biology and therapeutic responsiveness of this highly malignant pediatric brain tumor.",
author = "Jun Wang and Merino, {Diana M.} and Nicholas Light and Murphy, {Brian L.} and Wang, {Yong Dong} and Xiaohui Guo and Hodges, {Andrew P.} and Chau, {Lianne Q.} and Liu, {Kun Wei} and Girish Dhall and Shahab Asgharzadeh and Kiehna, {Erin N.} and Shirey, {Ryan J.} and Janda, {Kim D.} and Taylor, {Michael D.} and David Malkin and Ellison, {David W.} and VandenBerg, {Scott R.} and Eberhart, {Charles G.} and Rosalie Sears and Rousse, {Martine F.} and Gilbertson, {Richard J.} and Wechsler-Reya, {Robert J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1158/0008-5472.CAN-18-2565",
language = "English (US)",
volume = "79",
pages = "2208--2219",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Mycand loss of p53 cooperate to drive formation of choroid plexus carcinoma

AU - Wang, Jun

AU - Merino, Diana M.

AU - Light, Nicholas

AU - Murphy, Brian L.

AU - Wang, Yong Dong

AU - Guo, Xiaohui

AU - Hodges, Andrew P.

AU - Chau, Lianne Q.

AU - Liu, Kun Wei

AU - Dhall, Girish

AU - Asgharzadeh, Shahab

AU - Kiehna, Erin N.

AU - Shirey, Ryan J.

AU - Janda, Kim D.

AU - Taylor, Michael D.

AU - Malkin, David

AU - Ellison, David W.

AU - VandenBerg, Scott R.

AU - Eberhart, Charles G.

AU - Sears, Rosalie

AU - Rousse, Martine F.

AU - Gilbertson, Richard J.

AU - Wechsler-Reya, Robert J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Choroid plexus carcinoma (CPC) is a rare brain tumor that occurs most commonly in very young children and has a dismal prognosis despite intensive therapy. Improved outcomes for patients with CPC depend on a deeper understanding of the mechanisms underlying the disease. Here we developed transgenic models of CPCs by activating the Myc oncogene and deleting the Trp53 tumor suppressor gene in murine neural stem cells or progenitors. Murine CPC resembled their human counterparts at a histologic level, and like the hypodiploid subset of human CPC, exhibited multiple wholechromosome losses, particularly of chromosomes 8, 12, and 19. Analysis of murine and human CPC gene expression profiles and copy number changes revealed altered expression of genes involved in cell cycle, DNA damage response, and cilium function. High-throughput drug screening identified small molecule inhibitors that decreased the viability of CPC. These models will be valuable tools for understanding the biology of choroid plexus tumors and for testing novel approaches to therapy. Significance: This study describes new mouse models of choroid plexus carcinoma and uses them to investigate the biology and therapeutic responsiveness of this highly malignant pediatric brain tumor.

AB - Choroid plexus carcinoma (CPC) is a rare brain tumor that occurs most commonly in very young children and has a dismal prognosis despite intensive therapy. Improved outcomes for patients with CPC depend on a deeper understanding of the mechanisms underlying the disease. Here we developed transgenic models of CPCs by activating the Myc oncogene and deleting the Trp53 tumor suppressor gene in murine neural stem cells or progenitors. Murine CPC resembled their human counterparts at a histologic level, and like the hypodiploid subset of human CPC, exhibited multiple wholechromosome losses, particularly of chromosomes 8, 12, and 19. Analysis of murine and human CPC gene expression profiles and copy number changes revealed altered expression of genes involved in cell cycle, DNA damage response, and cilium function. High-throughput drug screening identified small molecule inhibitors that decreased the viability of CPC. These models will be valuable tools for understanding the biology of choroid plexus tumors and for testing novel approaches to therapy. Significance: This study describes new mouse models of choroid plexus carcinoma and uses them to investigate the biology and therapeutic responsiveness of this highly malignant pediatric brain tumor.

UR - http://www.scopus.com/inward/record.url?scp=85065510163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065510163&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-18-2565

DO - 10.1158/0008-5472.CAN-18-2565

M3 - Article

VL - 79

SP - 2208

EP - 2219

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 9

ER -